GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » Property, Plant and Equipment

CymaBay Therapeutics (CymaBay Therapeutics) Property, Plant and Equipment : $5.73 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics Property, Plant and Equipment?

CymaBay Therapeutics's quarterly net PPE declined from Jun. 2023 ($0.73 Mil) to Sep. 2023 ($0.51 Mil) but then increased from Sep. 2023 ($0.51 Mil) to Dec. 2023 ($5.73 Mil).

CymaBay Therapeutics's annual net PPE declined from Dec. 2021 ($1.43 Mil) to Dec. 2022 ($0.87 Mil) but then increased from Dec. 2022 ($0.87 Mil) to Dec. 2023 ($5.73 Mil).


CymaBay Therapeutics Property, Plant and Equipment Historical Data

The historical data trend for CymaBay Therapeutics's Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics Property, Plant and Equipment Chart

CymaBay Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Property, Plant and Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.64 2.03 1.43 0.87 5.73

CymaBay Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.87 0.73 0.51 5.73

CymaBay Therapeutics Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the companyFixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


CymaBay Therapeutics  (NAS:CBAY) Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


CymaBay Therapeutics Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103